



## ASX Release

### QUARTERLY AND HALF-YEAR REVIEW FOR THE PERIOD ENDED 30 JUNE 2019 AND BUSINESS UPDATE

**Melbourne, Australia; 26 July 2019:** Jayex Healthcare Limited (ASX: JHL) (**Jayex** or **Company**), a leading UK and Australian e-health provider of integrated healthcare services delivery platforms, today released its Appendix 4C – Quarterly cash flow report for the quarter ended 30 June 2019 (the **Quarter**).

- Net Profit for the UK operations for the half-year \$757,993 (up 50% on same period last year. H1 2018 \$506,093)
- Acute sales up 244% on the same period last year (H1 2019 \$577,865 / H1 2018 \$168,014)
- Jayex Partners with Microtech to offer Telehealth solutions in England, Wales, Australia and New Zealand
- New Zealand sales up 480% on same period last year
- Construction and fit-out of Medical Cannabis research facility in Papamoa, New Zealand completed on 19 July 2019
- Jayex Connect platform 649 customers using the new platform

In February 2019, Jayex Australia deployed their patient engagement and queue management systems (QMS) at the cohealth Health Centre Footscray, Victoria. This included the Self-check-in systems, patient workflow management, and patient calling and engagement solutions improving patient flow and staff efficiency.

Western Health awarded Jayex Australia their second contract to deploy patient management solutions in the new Joan Kirner Women's and Children's Hospital that launched in May 2019. Jayex is providing the new hospital with a Queue Management System (QMS) that improves patient access to Outpatient Services (OPS) by streamlining how patients present for their appointments. This includes the installation of 6 Touch Screen Self-Check-In Kiosks which include ticketing functionality, and 7 Queuing Display Screens that can be used to convey messages and call patients waiting for appointments.

In March 2019, Jayex won a contract to supply the Jayex Patient Check-in solution at the University Hospital Lewisham in London. The Enlighten patient management system was chosen to manage and minimise the time patients spend queuing and registering for their appointment. The Jayex solution will be deployed across a number of outpatient departments. Key features of the Enlighten Patient Check-in system at the University Hospital Lewisham will include 22 Self-check kiosk systems and Jayex's Patient workflow management system.

The Irish Government approved the development of a new children's hospital, to be co-located with St James's Hospital, which will be governed and managed by its own governing body and will bring together the services of three existing children's hospitals; Our Lady's Children's Hospital, Crumlin (OLCHC), Temple Street Children's University Hospital (TSCUH) and The paediatric services at Tallaght Hospital (AMNCH).

The new children's hospital will be supported by two Paediatric Outpatient Department and Urgent Care Centres, on the grounds of Tallaght Hospital (2020) and Connolly Hospital (2019).

When the new children's hospital opens in 2022 it will have a main campus alongside St. James's Hospital and two supporting Paediatric Outpatients and Urgent Care Centres (POPDUCC's) at Connolly (2019) and Tallaght (2020) hospitals, providing Ambulatory & Urgent Care Services for children in the greater Dublin region. A key part of the CHG digital hospital vision involves automated patient registration and calling, for which Jayex, in March 2019, was selected to deliver this solution.

This solution will not just meet the needs of the Connolly POPDUCC, but can also be scalable to meet the needs of the wider group across additional sites when required. Initially the system will be used for the outpatient department (two clinics initially in orthopaedic and general paediatrics with 2 Self-service kiosks & 4 calling screens). The Jayex system is scalable to include additional clinics and departments if required.

Jayex has been awarded the patient arrivals, engagement & call contract for the new Alfred Barrow Health and Wellbeing building in Barrow-in-Furness, Cumbria, due to open late 2019. The state-of-the art project will provide Primary and Community services to the public of the Barrow-in-Furness area and includes three individual GP Practices and provides accommodation for a number of community and secondary care services. Jayex was chosen, after a lengthy consultation and bidding process, to provide a "one size fits all" solution to allow patients with a booked appointment to access any one of the four electronic touch screen kiosks to "Self-Check-in" to the building advising where the patient should wait & instantly advise their service providers that the patient has arrived.

Jayex signed a distribution agreement on the 3 June 2019 with Microtech to distribute SurgeryPods in England, Wales, Australia and New Zealand. SurgeryPod is a user-friendly system designed to aid patients and clinicians to collect data and monitor physical health and psychological information. This is achieved via the measurement of vital signs and the use of validated health questionnaires. It is generally installed in the practice and hospital waiting rooms, so can be used without appointments. SurgeryPod significantly cuts down on waiting times for patient pre-assessment checks.

This year, Jayex has seen a lot of success in the New Zealand market, with a rapid increase in Practices using our queue management systems. Jayex is now working with additional Practice Management Systems (PMS) on integrations, and are due to start integrations with Jayex Arrive and Indici in August.

Since the last report, the construction and fit-out of the Company's wholly-owned subsidiary, Whakaora Hou Limited (WHL) special purpose medical cannabis research facility located at Papamoa on the north island of New Zealand research facility has been successfully completed (19 July 2019). The New Zealand Ministry of Health (MOH) have inspected the completed facility (19 July 2019) and WHL has been informed by the MOH that research licences will be granted shortly.

The granting of the research licences will allow WHL to conduct the pre-commercial cultivation of medical cannabis, cultivar yield, stability and productivity testing. This is a very pleasing result and reflects on the substantial efforts of the Group's personnel and advisors to complete this important first step toward commercial cultivation of medical cannabis in New Zealand. The NZ Government has announced that the commercial medical cannabis cultivation regulations will come into law in December, and will be followed in early 2020 by the issue of commercial cultivation licences. WHL will apply for a commercial licence at the appropriate time.

As of the end of June 2019, the new cloud based Jayex Connect platform had 649 active customers using it, with 770 Jayex Display media customers connected to it. In June 2019 the Company piloted Jayex Arrive to 12 of these 649 customers who are on the Jayex Connect platform. We expect Jayex Arrive to be available to all customer on supported Practice Management Systems in Q3 2019.

**Contacts for further information:**

Chief Executive Officer  
Nick Fernando  
1300 330 611  
[n.fernando@jayex.com](mailto:n.fernando@jayex.com)

Company Secretary  
Melanie Leydin  
0417 663 119

---

**About Jayex Healthcare Limited - [www.jayexhealthcare.com.au](http://www.jayexhealthcare.com.au)**

Jayex Healthcare is a leading provider in the United Kingdom and Australia of integrated healthcare services delivery platforms, incorporating the Company's four interconnected and proprietary technologies, being:

- the *Jayex Connect* – the complete cloud-based Patient Engagement Platform;
- the *Enlighten* patient workflow platform;
- the *Appointuit* patient engagement solution;
- the *Pharmacy Delivery 2 U* prescription delivery service; and
- the *BluePoint*<sup>®</sup> remote pharmacy prescription processing and dispensing terminal.

## Appendix 4C

### Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

**Name of entity**

JAYEX HEALTHCARE LIMITED

**ABN**

15 119 122 477

**Quarter ended ("current quarter")**

30 June 2019

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (6 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	2,653	4,580
1.2 Payments for		
(a) research and development	-	-
(b) product manufacturing and operating costs	(474)	(844)
(c) advertising and marketing	(26)	(63)
(d) leased assets	(79)	(119)
(e) staff costs	(786)	(1,607)
(f) administration and corporate costs	(994)	(1,713)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	(140)	(140)
1.6 Taxes paid	-	-
1.7 Other (provide details if material)	-	-
<b>1.8 Net cash from / (used in) operating activities</b>	<b>153</b>	<b>94</b>

<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire:		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (6 months) \$A'000</b>
2.2 Proceeds from disposal of:		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
<b>2.6 Net cash from / (used in) investing activities</b>	<b>-</b>	<b>-</b>

<b>3. Cash flows from financing activities</b>		
3.1 Proceeds from issues of shares	-	-
3.2 Proceeds from issue of convertible notes	-	-
3.3 Proceeds from exercise of share options	-	-
3.4 Transaction costs related to issues of shares, convertible notes or options	-	-
3.5 Proceeds from borrowings	-	100
3.6 Repayment of borrowings (interest)	-	-
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
<b>3.10 Net cash from / (used in) financing activities</b>	<b>-</b>	<b>100</b>

<b>4. Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1 Cash and cash equivalents at beginning of quarter/year to date	433	392
4.2 Net cash from / (used in) operating activities (item 1.8 above)	153	94
4.3 Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4 Net cash from / (used in) financing activities (item 3.10 above)	-	100

<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A'000</b>	<b>Year to date (6 months) \$A'000</b>
4.5	Effect of movement in exchange rates on cash held	-	-
<b>4.6</b>	<b>Cash and cash equivalents at end of quarter</b>	<b>586</b>	<b>586</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter \$A'000</b>	<b>Previous quarter \$A'000</b>
5.1	Bank balances	586	433
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>586</b>	<b>433</b>

**6. Payments to directors of the entity and their associates**

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

<b>Current quarter \$A'000</b>
40
-

Premises lease payments for the quarter.

**7. Payments to related entities of the entity and their associates**

- 7.1 Aggregate amount of payments to these parties included in item 1.2
- 7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

<b>Current quarter \$A'000</b>
-
-

Nil

8. <b>Financing facilities available</b> <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities	3,155	3,155
8.2 Credit standby arrangements	-	-
8.3 Other (please specify)	-	-
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

Facility amount	Lender	Interest rate	Secured/unsecured
\$2,000,000	Covenant Holdings (WA) Pty Ltd	8% per annum	Unsecured
\$1,000,000	Covenant Holdings (WA) Pty Ltd	12% per annum	Unsecured
\$155,000	Covenant Holdings (WA) Pty Ltd	Interest free	Unsecured


9. <b>Estimated cash outflows for next quarter</b>	\$A'000
9.1 Research and development	-
9.2 Product manufacturing and operating costs	(300)
9.3 Advertising and marketing	(25)
9.4 Leased assets	-
9.5 Staff costs	(800)
9.6 Administration and corporate costs	(800)
9.7 Other (provide details if material)	-
<b>9.8 Total estimated cash outflows</b>	<b>(1,925)</b>

\* Please note that the above estimated cash outflows for the next quarter do not include inflows of receipts from customers. The cash outflows are estimates only and variable outflows are calculated on forecast revenue for the quarter. Variable outflows will change if actual revenue differs from forecast revenue.

10. <b>Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)</b>	Acquisitions	Disposals
10.1 Name of entity	-	-
10.2 Place of incorporation or registration	-	-
10.3 Consideration for acquisition or disposal	-	-
10.4 Total net assets	-	-
10.5 Nature of business	-	-

**Compliance statement**

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here:  ..... Date: 26th July 2019  
(Company secretary)

Print name: .....MELANIE LEYDIN.....

**Notes**

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.